Adamas Announces New Employment Inducement Grant
September 11 2020 - 4:04PM
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that
the compensation committee of the company’s board of directors
granted two new employees the option to purchase an aggregate of
269,250 shares of the company’s common stock, at a per share
exercise price of $5.12, the closing trading price on September 8,
and restricted stock units to acquire 2,125 shares of the company’s
common stock. The stock options and restricted stock units vest
over four years and were granted pursuant to the Adamas
Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by
the company's board of directors in March 2016 under Rule
5653(c)(4) of the Nasdaq Global Market for equity grants to induce
new employees to enter into employment with the company.
About Adamas Pharmaceuticals, Inc. At
Adamas our vision is clear – to deliver innovative medicines that
reduce the burden of neurological diseases on patients, caregivers
and society. We are a fully integrated company focused on growing a
portfolio of therapies to address a range of neurological diseases.
In 2018, Adamas successfully launched GOCOVRI® (amantadine)
extended-release capsules, the first and only FDA-approved medicine
for the treatment of dyskinesia in patients with Parkinson’s
disease receiving levodopa-based therapy, with or without
concomitant dopaminergic medications. GOCOVRI is also the only
medicine clinically proven to reduce both dyskinesia and OFF. For
more information, please visit www.adamaspharma.com.
Contact:
Investors:Peter VozzoWestwicke Partners
443-213-0505peter.vozzo@westwicke.com
Media: Sarah MathiesonVice President, Communications &
Engagement 510-450-3528smathieson@adamaspharma.com
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Sep 2023 to Sep 2024